AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29407494 — intervention group
Group type: COMPARATOR
Intervention: Self‐Ligated Brackets (SLB) vs Conventional Elastomeric Ligated Brackets (ELB)
Number of subjects: 71
Study 29407494 — intervention group
Group type: COMPARATOR
Intervention: Clear Aligners (CLA) vs Conventional Elastomeric Ligated Brackets (ELB)
Number of subjects: 71
Study 26800106 — intervention group
Group type: EXPERIMENTAL
Intervention: Alitretinoin 30 mg once daily
Number of subjects: 33
Study 26800106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 24336915 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketorolac tromethamine, 0.45% (Acuvail), 4 times daily for 3 days before surgery
Number of subjects: 20
Study 22534404 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced left condition during the follicular phase
Number of subjects: 30
Study 22534404 — intervention group
Group type: COMPARATOR
Intervention: Menstrual phase
Number of subjects: 30
Study 22534404 — intervention group
Group type: COMPARATOR
Intervention: Luteal phase
Number of subjects: 30
Study 22534404 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular phase
Number of subjects: 30
Study 20117443 — intervention group
Group type: EXPERIMENTAL
Intervention: Freestyle bioprosthesis
Number of subjects: 166
Study 20117443 — intervention group
Group type: COMPARATOR
Intervention: Homograft
Number of subjects: 166
Study 18842192 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 2717
Study 18842192 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 2717
Study 18842192 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 2717
Study 18842192 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 2717
Study 16365072 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAA) supplementation at 7 graded intakes
Number of subjects: 6
Study 14551359 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (normotensive group)
Number of subjects: 89
Study 14551359 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (hypertensive group)
Number of subjects: 89
Study 14551359 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normotensive group)
Number of subjects: 89
Study 14551359 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (hypertensive group)
Number of subjects: 89
Study 10754614 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron
Number of subjects: 2061
Study 10754614 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg droperidol
Number of subjects: 2061
Study 10754614 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg droperidol
Number of subjects: 2061
Study 10754614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2061
Study 10754614 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antiemetic therapy (any active treatment)
Number of subjects: 2061
Study 8726201 — intervention group
Group type: EXPERIMENTAL
Intervention: Andrews-type table
Number of subjects: 101
Study 8726201 — intervention group
Group type: COMPARATOR
Intervention: four-poster-type frame
Number of subjects: 101
Study 1425820 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg/day)
Number of subjects: 800
Study 1425820 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg/day) alone or in combination with tocopherol
Number of subjects: 800
Study 1425820 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 800
Study 3904132 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous administration of Estracyt
Number of subjects: 95
Study 3904132 — intervention group
Group type: COMPARATOR
Intervention: Intermittent administration of Estracyt
Number of subjects: 95
Study 31446646 — intervention group
Group type: EXPERIMENTAL
Intervention: TNBG-5602
Number of subjects: 0
Study 28982833 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise intervention including customised text message invitation, automated phone call invitation, secretary phone call, family health professional phone call and face-to-face appointment.
Number of subjects: 0
Study 28982833 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise intervention (text messages, phone calls, appointments)
Number of subjects: 0
Study 28982833 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (written letter)
Number of subjects: 0
Study 26296954 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine 60 mg/m(2) daily × 5
Number of subjects: 93
Study 26296954 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine 90 mg/m(2) daily × 5
Number of subjects: 93
Study 26296954 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine (various doses)
Number of subjects: 93
Study 23365035 — intervention group
Group type: EXPERIMENTAL
Intervention: WOMAC function items assessment pre-operatively and at 3, 6, 12, and 24 months follow-up
Number of subjects: 1198
Study 21555686 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib plus docetaxel (docetaxel 80 mg/m2 once every 3 weeks plus axitinib 5 mg twice per day)
Number of subjects: 168
Study 21555686 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus docetaxel (docetaxel 80 mg/m2 once every 3 weeks plus placebo)
Number of subjects: 168
Study 21555686 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib plus docetaxel
Number of subjects: 168
Study 21555686 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus docetaxel
Number of subjects: 168
Study 18057309 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum beta(2)-microglobulin levels
Number of subjects: 1813
Study 18057309 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative mean Kt/V of beta(2)-microglobulin
Number of subjects: 1813
Study 18057309 — intervention group
Group type: COMPARATOR
Intervention: High-flux dialysis
Number of subjects: 1813
Study 16931508 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (2 mg single evening dose)
Number of subjects: 43
Study 15252155 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 13
Study 10833188 — intervention group
Group type: EXPERIMENTAL
Intervention: Babyhaler with mask
Number of subjects: 40
Study 10833188 — intervention group
Group type: COMPARATOR
Intervention: Babyhaler with mouthpiece
Number of subjects: 40
Study 10833188 — intervention group
Group type: COMPARATOR
Intervention: Aerochamber with mask
Number of subjects: 40
Study 10833188 — intervention group
Group type: COMPARATOR
Intervention: Babyhaler
Number of subjects: 40
Study 10833188 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml bottle
Number of subjects: 40
Study 9061387 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (100 micrograms every 3 hours)
Number of subjects: 40
Study 9061387 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol (100 micrograms every 3 hours)
Number of subjects: 40
Study 8464662 — intervention group
Group type: EXPERIMENTAL
Intervention: C/B ADTP booster
Number of subjects: 139
Study 4032272 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 X 100‐mg chewable tablets chewed before swallowing (CHEW)
Number of subjects: 6
Study 4032272 — intervention group
Group type: COMPARATOR
Intervention: 2 X 200‐mg conventional tablets (CT)
Number of subjects: 6
Study 4032272 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 X 100‐mg chewable tablets swallowed whole (SW)
Number of subjects: 6
Study 4032272 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg b.i.d. (projected steady-state)
Number of subjects: 6
Study 4032272 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg b.i.d. (steady state)
Number of subjects: 6
Study 31401661 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning models using QCT features
Number of subjects: 80
Study 29739423 — intervention group
Group type: EXPERIMENTAL
Intervention: iSupport, an online self-help training and support program with a maximum of 23 lessons covering various topics related to dementia.
Number of subjects: 208
Study 29739423 — intervention group
Group type: EXPERIMENTAL
Intervention: iSupport, an online self-help training and support program.
Number of subjects: 208
Study 29739423 — intervention group
Group type: COMPARATOR
Intervention: Education-only e-book (comparison group).
Number of subjects: 208
Study 26721546 — intervention group
Group type: EXPERIMENTAL
Intervention: IB-CBSM
Number of subjects: 58
Study 26721546 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 58
Study 26721546 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 58
Study 23845064 — intervention group
Group type: EXPERIMENTAL
Intervention: Family CBT with a five-session program of BPAM (n=109)
Number of subjects: 209
Study 23845064 — intervention group
Group type: COMPARATOR
Intervention: Family CBT-only (n=100)
Number of subjects: 209
Study 23845064 — intervention group
Group type: EXPERIMENTAL
Intervention: BPAM
Number of subjects: 209
Study 23845064 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with nonanxious parents
Number of subjects: 209
Study 22525310 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous incubated macrophages
Number of subjects: 43
Study 22525310 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 43
Study 20204340 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotomy (PNL)
Number of subjects: 40
Study 20204340 — intervention group
Group type: COMPARATOR
Intervention: Open surgery nephrolithotomy
Number of subjects: 40
Study 20204340 — intervention group
Group type: EXPERIMENTAL
Intervention: PNL
Number of subjects: 40
Study 20204340 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 40
Study 17588301 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release nicotinic acid (Niaspan) at a maximum dose of 2000 mg/day
Number of subjects: 1053
Study 17588301 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release nicotinic acid (Niaspan)
Number of subjects: 1053
Study 16217231 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnea self‐management program plus 24 supervised exercise sessions (DM‐training)
Number of subjects: 103
Study 16217231 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnea self‐management program plus 4 supervised exercise sessions (DM‐exposure)
Number of subjects: 103
Study 16217231 — intervention group
Group type: COMPARATOR
Intervention: Dyspnea self‐management program (DM)
Number of subjects: 103
Study 16217231 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (DM, DM-exposure, DM-training)
Number of subjects: 103
Study 11956255 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening (chest x-ray and cytology)
Number of subjects: 9192
Study 10191795 — intervention group
Group type: EXPERIMENTAL
Intervention: SSA-VA Joint Initiative
Number of subjects: 6709
Study 10191795 — intervention group
Group type: COMPARATOR
Intervention: Comparison HCHV sites
Number of subjects: 6709
Study 7546497 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 108
Study 7546497 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 108
Study 2339081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholescintigraphy
Number of subjects: 0
Study 2339081 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cholecystography
Number of subjects: 0
Study 373995 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen 600 mg daily
Number of subjects: 24
Study 373995 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 1200 mg daily
Number of subjects: 24
Study 31111678 — intervention group
Group type: EXPERIMENTAL
Intervention: ramucirumab as a single agent
Number of subjects: 0
Study 31111678 — intervention group
Group type: EXPERIMENTAL
Intervention: ramucirumab plus paclitaxel
Number of subjects: 0
Study 31111678 — intervention group
Group type: EXPERIMENTAL
Intervention: apatinib as a third-line or later treatment
Number of subjects: 0
Study 31111678 — intervention group
Group type: EXPERIMENTAL
Intervention: ramucirumab plus immune checkpoint inhibitors
Number of subjects: 0
Study 31111678 — intervention group
Group type: EXPERIMENTAL
Intervention: apatinib in combination with cytotoxic agents
Number of subjects: 0
Study 31111678 — intervention group
Group type: EXPERIMENTAL
Intervention: regorafenib
Number of subjects: 0
Study 30518584 — intervention group
Group type: EXPERIMENTAL
Intervention: Establishment of a trauma treatment team in the experimental group
Number of subjects: 98
Study 30518584 — intervention group
Group type: COMPARATOR
Intervention: Basic treatments in both experimental and control groups
Number of subjects: 98
Study 26574958 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance (measured by HOMA-IR)
Number of subjects: 147
Study 26574958 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-1
Number of subjects: 147
Study 26574958 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA-IR
Number of subjects: 147
Study 25014920 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit attempt initiated the day after the first session
Number of subjects: 176
Study 22174431 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 75 mg
Number of subjects: 754
Study 22174431 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 754
Study 22174431 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 754
Study 22174431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 754
Study 19047289 — intervention group
Group type: EXPERIMENTAL
Intervention: ProMACE-CytaBOM (63 patients)
Number of subjects: 899
Study 19047289 — intervention group
Group type: EXPERIMENTAL
Intervention: m-BACOD (58 patients)
Number of subjects: 899
Study 19047289 — intervention group
Group type: COMPARATOR
Intervention: CHOP or MACOP-B (not specified number)
Number of subjects: 899
Study 19047289 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS relapse
Number of subjects: 899
Study 17961835 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg
Number of subjects: 20
Study 15470334 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroflurbiprofen (100 mg)
Number of subjects: 12
Study 15470334 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen (65 mg)
Number of subjects: 12
Study 12042232 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone 400-600 mg/day
Number of subjects: 40
Study 12042232 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine 20-40 mg/day
Number of subjects: 40
Study 10457212 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with vitamin E-rich sunflower oil
Number of subjects: 0
Study 10457212 — intervention group
Group type: COMPARATOR
Intervention: Dietary supplementation with provitamin A-containing red palm oil
Number of subjects: 0
Study 8547546 — intervention group
Group type: COMPARATOR
Intervention: Sodium Nitroprusside (SNP)
Number of subjects: 20
Study 8547546 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone
Number of subjects: 20
Study 1688499 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous gammaglobulin (IV‐IgG) at a dose of 400 mg/kg for 5 days
Number of subjects: 12
Study 1688499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 832607 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 56
Study 832607 — intervention group
Group type: COMPARATOR
Intervention: Operation only
Number of subjects: 56
Study 31383945 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface measurement (SM) method
Number of subjects: 200
Study 31383945 — intervention group
Group type: COMPARATOR
Intervention: Birth weight (BW) method
Number of subjects: 200
Study 31383945 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface measurement (SM) method among BW < 1000 g
Number of subjects: 200
Study 31383945 — intervention group
Group type: COMPARATOR
Intervention: Birth weight (BW) method among BW < 1000 g
Number of subjects: 200
Study 31694493 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-weight central obesity measured by waist circumference
Number of subjects: 0
Study 31694493 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-weight central obesity measured by waist-to-hip ratio
Number of subjects: 0
Study 31694493 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-weight central obesity measured by visceral fat thickness
Number of subjects: 0
Study 31694493 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-weight central obesity measured by subcutaneous fat thickness
Number of subjects: 0
Study 27522981 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet gel
Number of subjects: 56
Study 27522981 — intervention group
Group type: COMPARATOR
Intervention: Antiseptic ointment dressing
Number of subjects: 56
Study 25844614 — intervention group
Group type: COMPARATOR
Intervention: HSP cleansing head
Number of subjects: 0
Study 25844614 — intervention group
Group type: EXPERIMENTAL
Intervention: HSP skin smoothing head
Number of subjects: 0
Study 25844614 — intervention group
Group type: EXPERIMENTAL
Intervention: HSP infusion head
Number of subjects: 0
Study 23637110 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint crisis plan in addition to treatment as usual (TAU)
Number of subjects: 88
Study 23637110 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 88
Study 22922860 — intervention group
Group type: EXPERIMENTAL
Intervention: IV iron (iv sucrose)
Number of subjects: 0
Study 22922860 — intervention group
Group type: COMPARATOR
Intervention: Oral iron (iron fumarate)
Number of subjects: 0
Study 19252142 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST) 3 sessions per week for 24 weeks
Number of subjects: 0
Study 19252142 — intervention group
Group type: COMPARATOR
Intervention: Untrained (UN) group
Number of subjects: 0
Study 17106312 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure measurements
Number of subjects: 0
Study 17106312 — intervention group
Group type: COMPARATOR
Intervention: Physician blood pressure measurements
Number of subjects: 0
Study 15724865 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium therapy (Magne B(6)R, Sanofi‐Synthelabo)
Number of subjects: 53
Study 15724865 — intervention group
Group type: COMPARATOR
Intervention: Control group (no magnesium therapy)
Number of subjects: 53
Study 15724865 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium therapy
Number of subjects: 53
Study 15320920 — intervention group
Group type: EXPERIMENTAL
Intervention: School breakfast clubs in primary schools
Number of subjects: 0
Study 15320920 — intervention group
Group type: EXPERIMENTAL
Intervention: School breakfast clubs in secondary schools
Number of subjects: 0
Study 10022184 — intervention group
Group type: EXPERIMENTAL
Intervention: Etching for 60 seconds with 37% phosphoric acid
Number of subjects: 60
Study 10022184 — intervention group
Group type: COMPARATOR
Intervention: Etching for 15 seconds with 37% phosphoric acid
Number of subjects: 60
Study 7485860 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin (0.3%)
Number of subjects: 308
Study 7485860 — intervention group
Group type: COMPARATOR
Intervention: Topical gentamicin (0.3%)
Number of subjects: 308
Study 2404660 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pharmacotherapy plus cognitive-behavioral psychotherapy
Number of subjects: 0
Study 2404660 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 0
Study 7197978 — intervention group
Group type: EXPERIMENTAL
Intervention: Amezinium 10 mg i.v.
Number of subjects: 33
Study 7197978 — intervention group
Group type: EXPERIMENTAL
Intervention: Amezinium (various p.o. doses)
Number of subjects: 33
Study 7197978 — intervention group
Group type: COMPARATOR
Intervention: Norfenefrine 10 mg i.m. and 40 mg p.o.
Number of subjects: 33
Study 7197978 — intervention group
Group type: COMPARATOR
Intervention: Dihydroergotamine 1 mg i.m. and 4 mg p.o.
Number of subjects: 33
Study 31418881 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 4%
Number of subjects: 20
Study 31418881 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 20
Study 31699131 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (15 mg/kg IV-TXA + 2 g topical TXA)
Number of subjects: 180
Study 31699131 — intervention group
Group type: COMPARATOR
Intervention: IV group (15 mg/kg IV-TXA)
Number of subjects: 180
Study 28081719 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic Prophylaxis (AP) continued
Number of subjects: 176
Study 28081719 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic Prophylaxis (AP) stopped
Number of subjects: 176
Study 25618516 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant rs1458038 near FGF5
Number of subjects: 7319
Study 25618516 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant rs11105378 near ATP2B1
Number of subjects: 7319
Study 25618516 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant rs1378942 near CSK
Number of subjects: 7319
Study 23608160 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of anxiety disorder with depression, mental health-related impairment, and social support factors
Number of subjects: 0
Study 21873796 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory training and aerobic exercise for 1 year
Number of subjects: 122
Study 19466476 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine + Psychoeducation
Number of subjects: 99
Study 19466476 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Psychoeducation
Number of subjects: 99
Study 17150319 — intervention group
Group type: EXPERIMENTAL
Intervention: Chios mastic powder (5g daily, high-dose group)
Number of subjects: 133
Study 17150319 — intervention group
Group type: EXPERIMENTAL
Intervention: Chios mastic solution (low-dose group)
Number of subjects: 133
Study 15522140 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried garlic powder tablets (10.8 mg alliin/d, corresponding to about three garlic cloves)
Number of subjects: 75
Study 15522140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 11509678 — intervention group
Group type: EXPERIMENTAL
Intervention: methylprednisolone and chlorambucil
Number of subjects: 3
Study 11509678 — intervention group
Group type: EXPERIMENTAL
Intervention: methylprednisolone/chlorambucil
Number of subjects: 3
Study 11509678 — intervention group
Group type: COMPARATOR
Intervention: methylprednisolone alone
Number of subjects: 3